Integrin α5β1 therapy (Eli Lilly and Company)
N/A
Report date: 2025/12/08 17:13:59
Base Information
Drug NameIntegrin α5β1 therapy (Eli Lilly and Company)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A